Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients

Uwe Platzbecker, Emanuele Angelucci, Pau Montesinos, Roberto Massimo Lemoli, Alexandros Spyridonidis, Tariq I. Mughal, Carole Paley, Marcello Riggi, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 11710–11712.

https://doi.org/10.1182/blood-2022-160127

Published: 2022

Journal Articles

Preliminary Results from an Observational Multicenter Study of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp in the European Expanded Access Program

Eric Deconinck, Madhu Anant, David Manteigas, Carole Paley, Marcello Riggi, Marco Herling, Emanuele Angelucci

Blood (2022) 140 (Supplement 1): 8115–8116.

https://doi.org/10.1182/blood-2022-159942

Published: 2022

Journal Articles

Tagraxofusp Administered Concomitantly with Intrathecal Chemotherapy in Patients with BPDCN who Either Have or are Considered High-risk to Develop CNS Disease is a Safe and Effective Treatment Strategy: An Italian Multicenter Experience

Giulia Rivoli, Germana Beltrami, Anna M. Raiola, Carole Paley, Marcello Riggi, Alida Dominietto, Emanuele Angelucci

Blood (2022) 140 (Supplement 1): 13271–13272.

https://doi.org/10.1182/blood-2022-158985

Published: 2022

Journal Articles

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial

Naveen Pemmaraju, Marina Konopleva, Kendra Sweet, Anthony S. Stein, Sumithira Vasu, David A Rizzieri, Eunice S. Wang, Hagop Kantarjian, Christopher L. Brooks, Carole Paley, Tariq I. Mughal, Andrew A. Lane

Blood (2022) 140 (Supplement 1): 6155–6157.

https://doi.org/10.1182/blood-2022-159970

Published: 2022

Journal Articles

Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study

Steffen Koschmieder, Clemens Schulte, Eyck von der Heyde, Lambert Busque, Françoise Boyer-Perrard, Timothy Devos, Francesco Passamonti, Mike W. Zuurman, Carole Paley, Geralyn Gilotti, Wendy Y. Cheng, Chi Gao, Mu Cheng, Melody Wu, Mei Sheng Duh, Claire N. Harrison

Blood (2021) 138 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2021-148254

Published: 2021

Journal Articles

Clinical Outcomes Among Patients with Myelodysplastic Syndromes Treated with Iron Chelation Therapy: A Real World Medicare Database Study

Yanni Hao, PhD, Alex Z Fu, PhD, Austin Coe, Ying Qiu, PhD, Zhiyi Li, Becky Hanna, Jackson Tang, Brian M. Elliott, MD, Carole Paley, MD

Blood (2016) 128 (22): 2396.

https://doi.org/10.1182/blood.V128.22.2396.2396

Published: 2016

Journal Articles

Treatment Patterns and Adherence Among Patients with Myelodysplastic Syndromes Receiving Deferasirox As Iron Chelation Therapy: A Real World Medicare Database Study

Alex Z Fu, PhD, Yanni Hao, PhD, Austin Coe, Ying Qiu, PhD, Zhiyi Li, Becky Hanna, Jackson Tang, Brian M. Elliott, MD, Carole Paley, MD

Blood (2016) 128 (22): 4759.

https://doi.org/10.1182/blood.V128.22.4759.4759

Published: 2016

Journal Articles

Epidemiologic and Clinical Characteristics of Thalassemia (Thal) Intermedia (TI) in the United States

Elliott P. Vichinsky, MD, Janet Kwiatkowski, MD, Patricia J. Giardina, MD, Carole Paley, MD, Francis Vekeman, MA, Wendy Y. Cheng, MPH, MPhil, Joseph Damron, BA, Nora McCormick, MSc, Medha Sasane, PhDBPharm,MS, Ying Qiu, PhD, Mei Sheng Duh, MPH, ScD, Alexis A. Thompson, MD

Blood (2015) 126 (23): 3279.

https://doi.org/10.1182/blood.V126.23.3279.3279

Published: 2015

Journal Articles

Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial

Matthew M. Heeney, MD FRCP(C), Brad Baltz, MD, Patricia Adams-Graves, MD, Elizabeth Yang, MD PhD, Carole Paley, MD, Jason Esposito, MSHS, Katie McNamara, MSHS, CCRA, Elliott Vichinsky, MD, Alex George, MD, PhD

Blood (2014) 124 (21): 4890.

https://doi.org/10.1182/blood.V124.21.4890.4890

Published: 2014

Journal Articles

Comparison of Real-World Treatment Patterns and Clinical Outcomes in 18-59 Year-Old Patients with FLT3 Mutated Vs. FLT3 Wild Type Acute Myeloid Leukemia: A Medical Records Review

Jipan Xie, MD PhD, Emily Goldmann, MPH, PhD, Anuja Roy, PhD MBA, Chelsey Yang, BA, Eric Q Wu, PhD, Carole Paley, MD

Blood (2014) 124 (21): 5992.

https://doi.org/10.1182/blood.V124.21.5992.5992

Published: 2014

Journal Articles

Adherence to Iron Chelation Therapy and Associated Healthcare Resource Utilization and Costs in Medicaid Patients with Sickle Cell Disease

Francis Vekeman, MA, Medha Sasane, BPharm, PhD, Wendy Y Cheng, MPH, MPhil, Agnihotram V Ramanakumar, PhD, Jonathan Fortier, MA, Mei S. Duh, ScD, MPH, Carole Paley, MD, Patricia Adams-Graves, MD

Blood (2014) 124 (21): 2177.

https://doi.org/10.1182/blood.V124.21.2177.2177

Published: 2014

Journal Articles

Relationship Between Chelation and Clinical Outcomes in Lower-Risk Patients with Myelodysplastic Syndrome (MDS): Registry Analysis at 5 Years

Roger M. Lyons, MD, Billie J. Marek, MD, Carole Paley, MD, Jason Esposito, MSHS, Katie McNamara, MSHS, CCRA, Lawrence Garbo, MD, Nicholas DiBella, MD, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 1350.

https://doi.org/10.1182/blood.V124.21.1350.1350

Published: 2014

Journal Articles

Pituitary Iron and Volume Are Affecting Hormones and Reproductive Potential

Sylvia T Singer, MD, Jerry Wang, MD, Qing Yuan, PhD, Elliott Vichinsky, MD, James Smith, MD, Carole Paley, MD, Roland Fischer, PhD

Blood (2014) 124 (21): 4048.

https://doi.org/10.1182/blood.V124.21.4048.4048

Published: 2014

Journal Articles

Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Matthew M Heeney, MD, Brigitta U. Mueller, MD, Brad Baltz, MD, Patricia Adams-Graves, MD, Elizabeth Yang, MD, PhD, Carole Paley, MD, Jason Esposito MSHS, McNamara Katie MSHS CCRA, Elliott Vichinsky, MD

Blood (2013) 122 (21): 988.

https://doi.org/10.1182/blood.V122.21.988.988

Published: 2013

Journal Articles

Medical Complications In Patients With Myelofibrosis By Frequency Of Blood Transfusion and Iron Chelation Therapy

Francis Vekeman, MA, Wendy Y Cheng, MPH, MPhil, Medha Sasane, BPharm, PhD, Lynn Huynh, MPH, MBA, DrPH, Michael Kaminsky, BA, Mei S. Duh, ScD, MPH, Carole Paley, MD, Ruben A. Mesa, MD

Blood (2013) 122 (21): 2964.

https://doi.org/10.1182/blood.V122.21.2964.2964

Published: 2013

Journal Articles

PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma

Paul G. Richardson, MD, Melissa Alsina, MD, Donna Weber, MD, Steven E. Coutre, MD, Sagar Lonial, MD, Cristina Gasparetto, MD, Sutapa Mukhopadhyay, PhD, Michael Ondovik, PharmD, MBA, Mahmudul Khan, PhD, Carole Paley, MD, Robert Schlossman, MD

Blood (2012) 120 (21): 1852.

https://doi.org/10.1182/blood.V120.21.1852.1852

Published: 2012

Journal Articles

12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Matthew M. Heeney, MD, Brigitta U. Mueller, MD, Brad Baltz, MD, Patricia Adams-Graves, MD, Elizabeth Yang, MD, PhD, Carole Paley, MD, Jason Esposito, MSHS, Elliott P. Vichinsky, MD

Blood (2012) 120 (21): 1010.

https://doi.org/10.1182/blood.V120.21.1010.1010

Published: 2012

Journal Articles

Utilization Patterns of Iron Chelation Therapy in Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D.

Amer M. Zeidan, MD, Maria R. Baer, M.D., Steven D. Gore, MD, Medha Sasane, BPharm, PhD, Carole Paley, MD, Diane L. McNally, BSPharm, M.S., Amy J. Davidoff, M.S., Ph.D.

Blood (2012) 120 (21): 3178.

https://doi.org/10.1182/blood.V120.21.3178.3178

Published: 2012

Journal Articles

Age-Related Emergency Department Reliance and Healthcare Resource Utilization in Patients with Sickle Cell Disease

Morey A. Blinder, MD, Francis Vekeman, MA, Medha Sasane, BPharm, PhD, Alex Trahey, BS, Carole Paley, MD, Matthew Magestro, MBA, MS, Mei S. Duh, ScD, MPH

Blood (2012) 120 (21): 475.

https://doi.org/10.1182/blood.V120.21.475.475

Published: 2012

Journal Articles

Changes in Pituitary Iron, Volume, and Function Over Two Years in Pediatric Patients Treated with Deferasirox

John C Wood, MD, Ph.D, Leila Noetzli, BS, Ashok Panigrahy, MD, Carole Paley, MD, Ani Dongelyan, BA, Tatiana Hernandez, BA, CCRP, Vasilios Berdoukas, MB, BS, Thomas D. Coates, MD

Blood (2012) 120 (21): 3206.

https://doi.org/10.1182/blood.V120.21.3206.3206

Published: 2012

NARROW

Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients

Preliminary Results from an Observational Multicenter Study of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp in the European Expanded Access Program

Tagraxofusp Administered Concomitantly with Intrathecal Chemotherapy in Patients with BPDCN who Either Have or are Considered High-risk to Develop CNS Disease is a Safe and Effective Treatment Strategy: An Italian Multicenter Experience

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial

Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study

Clinical Outcomes Among Patients with Myelodysplastic Syndromes Treated with Iron Chelation Therapy: A Real World Medicare Database Study

Treatment Patterns and Adherence Among Patients with Myelodysplastic Syndromes Receiving Deferasirox As Iron Chelation Therapy: A Real World Medicare Database Study

Epidemiologic and Clinical Characteristics of Thalassemia (Thal) Intermedia (TI) in the United States

Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial

Comparison of Real-World Treatment Patterns and Clinical Outcomes in 18-59 Year-Old Patients with FLT3 Mutated Vs. FLT3 Wild Type Acute Myeloid Leukemia: A Medical Records Review

Adherence to Iron Chelation Therapy and Associated Healthcare Resource Utilization and Costs in Medicaid Patients with Sickle Cell Disease

Relationship Between Chelation and Clinical Outcomes in Lower-Risk Patients with Myelodysplastic Syndrome (MDS): Registry Analysis at 5 Years

Pituitary Iron and Volume Are Affecting Hormones and Reproductive Potential

Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Medical Complications In Patients With Myelofibrosis By Frequency Of Blood Transfusion and Iron Chelation Therapy

PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma

12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Utilization Patterns of Iron Chelation Therapy in Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D.

Age-Related Emergency Department Reliance and Healthcare Resource Utilization in Patients with Sickle Cell Disease

Changes in Pituitary Iron, Volume, and Function Over Two Years in Pediatric Patients Treated with Deferasirox

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only